Kristine Mørch
Associate Professor, Head National Center for Tropical Infectious Diseases, Haukeland University Hospital
- E-mailkristine.morch@uib.no
- Phone004755975660
- Visitor AddressDepartment of Medicine, Haukeland University Hospital5021 Bergen
- Postal AddressPostboks 78045020 Bergen
Kristine Mørch, MD, PhD, is head of National Center for Tropical Infectious Diseases at Infectious Diseases Section, Department of Medicine, Haukeland university hospital. She is also associate professor at Department of Clinical Science, University of Bergen. Her main research interest is the field of tropical infectious diseases, particularly acute febrile diseases and malaria, as well as giardiasis with focus on resistance and treatment of metronidazol refractory infections.
Academic article
- (2024). Ein mann i 60-åra med livstrugande febersjukdom etter utanlandsreise. Tidsskrift for Den norske legeforening.
- (2023). Clinical features and risk factors for death in acute undifferentiated fever: A prospective observational study in rural community hospitals in six states of India. Transactions of the Royal Society of Tropical Medicine and Hygiene. 91-101.
- (2022). No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection. Journal of Gastroenterology and Hepatology Open (JGH Open). 185-188.
- (2022). Malaria prevalence and performance of diagnostic tests among patients hospitalized with acute undifferentiated fever in Zanzibar. Malaria Journal. 1-8.
- (2021). Schistosomiasis hos norske studenter etter opphold i Afrika. Tidsskrift for Den norske legeforening. 243-247.
- (2021). Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology. 849-854.
- (2021). Leishmaniasis i Norge. Tidsskrift for Den norske legeforening. 1-9.
- (2021). Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: A TropNet Study. Clinical Infectious Diseases. 1517-1523.
- (2021). Antibiotics for gastroenteritis in general practice and out-of-hours services in Norway 2006-15. Family Practice. 19-25.
- (2020). The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. PLOS ONE. 1-16.
- (2020). Giardiasis treatment: an update with a focus on refractory disease. Current Opinion in Infectious Diseases. 355-364.
- (2020). Detection of remaining Plasmodium DNA and gametocytes during follow up after curative malaria treatment among returned travellers in Norway. Malaria Journal.
- (2020). Bacteraemia, malaria, and case fatality among children hospitalized with fever in Dar es Salaam, Tanzania. Frontiers in Microbiology. 1-10.
- (2019). En mann i 80-årene med leddgikt og vedvarende feber. Tidsskrift for Den norske legeforening. 6 pages.
- (2019). Assessment of malaria real-time PCR methods and application with focus on lowlevel parasitaemia. PLOS ONE. 1-15.
- (2017). Severe malaria in Europe: an 8-year multi-centre observational study. Malaria Journal. 1-11.
- (2017). Serovar prevalence of leptospira in semirural India and the development of an igm-based indirect ELISA. Journal of Infection in Developing Countries. 234-241.
- (2017). Schistosomiasis in european travelers and migrants: Analysis of 14 years tropnet surveillance data. American Journal of Tropical Medicine and Hygiene. 567-574.
- (2017). Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. BMC Immunology. 1-8.
- (2017). Acute undifferentiated fever in India: A multicentre study of aetiology and diagnostic accuracy. BMC Infectious Diseases. 1-11.
- (2016). Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scandinavian Journal of Gastroenterology. 337-343.
- (2016). Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis. Neurogastroenterology and Motility. 1561-1569.
- (2016). A high malaria prevalence identified by PCR among patients with acute undifferentiated fever in India. PLOS ONE.
- (2015). Schistosomiasis in pregnant travelers: A case series. Journal of Travel Medicine (JTM). 94-98.
- (2015). Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study. Clinical Infectious Diseases. 1441-1444.
- (2015). Beredskap ved alvorlig malaria. Tidsskrift for Den norske legeforening. 533-535.
- (2014). Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2131-2139.
- (2014). Irritable bowel syndrome and chronic fatigue 6 years after Giardia infection: A controlled prospective cohort study. Clinical Infectious Diseases. 1394-1400.
- (2014). A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLOS ONE.
- (2013). Fever in the tropics: aetiology and case-fatality - a prospective observational study in a tertiary care hospital in South India. BMC Infectious Diseases. 8 pages.
- (2013). Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterology. 17 pages.
- (2013). A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway. Malaria Journal. 8 pages.
- (2012). The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years after Giardia infection. A historic cohort study. Scandinavian Journal of Gastroenterology. 956-961.
- (2012). PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Medical Genetics. 7 pages.
- (2012). Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 214-219.
- (2012). Impact of Obesity on the Bioavailability of Peginterferon-alpha 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. PLOS ONE. 7 pages.
- (2012). Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLOS ONE. 7 pages.
- (2012). Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome. BMC Infectious Diseases. 258.
- (2012). Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. European Journal of Clinical Microbiology and Infectious Diseases. 1631-1635.
- (2011). Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. Journal of Viral Hepatitis. 245-251.
- (2011). Intravenous Artesunate for Severe Malaria in Travelers, Europe. Emerging Infectious Diseases. 771-777.
- (2011). Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. Journal of Infectious Diseases. 1748-1752.
- (2011). Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of Viral Hepatitis. 1-7.
- (2010). Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Clinical Infectious Diseases. E22-E25.
- (2010). Giardiasis: the ever-present threat of a neglected disease. Current Drug Targets - Infectious Disorders. 329-348.
- (2010). Giardiasis ? why do the symptoms sometimes never stop? Trends in Parasitology. 75-82.
- (2010). Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 430-435.
- (2009). Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after. BMC Infectious Diseases.
- (2009). High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 530-532.
- (2008). Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. Journal of Infection. 268-273.
- (2008). Sensitivity of a Giardia antigen test in persistent giardiasis following an extensive outbreak. Clinical Microbiology and Infection (CMI). 1069-1071.
- (2008). Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 1837-1835.
- (2008). Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: A randomized open clinical trial. Scandinavian Journal of Infectious Diseases. 517-522.
Editorial
- (2022). Apekopper i Norge. Tidsskrift for Den norske legeforening.
Reader opinion piece
- (2015). Hund som Giardia-kilde i Bergen i 2004 - barking up the wrong tree? Tidsskrift for Den norske legeforening. 1718-1720.
- (2011). Early determination of Hepatitis C virus RNA may help to decide the duration of therapy for chronic Hepatitis C virus genotype 2/3 infection. Hepatology. 1067-1068.
- (2008). Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology. 695-695.
Short communication
- (2015). Severe human Babesia divergens infection in Norway. International Journal of Infectious Diseases. 37-38.
Feature article
- (2013). Utveksling av helsepersonell mellom Bergen og Zanzibar. Tidsskrift for Den norske legeforening. 187-189.
Doctoral dissertation
- (2019). PCR based Malaria diagnostics – Method development and application.
- (2010). Giardiasis - with emphasis on treatment and post-infectious manifestations.
Abstract
- (2012). Impact of Inosine Triphosphatase (ITPA) Gene Variants on Anemia, Ribavirin Concentrations, and Outcome During Therapy for HCV Genotype 2/3. Hepatology. 1023A-1023A.
- (2012). A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. Hepatology. 682A-683A.
- (2011). Impact of obesity on the bioavailability of peginterferon-alpha 2A and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. Hepatology. 1321A-1322A.
- (2010). IMPORTANCE OF HCV CORE ANTIGEN BELOW 0.2 PG/ML DAY 3 IN SHORT-TERM PEG-INTERFERON THERAPY FOR CHRONIC GENOTYPE2/3 INFECTION. Hepatology. 813A-813A.
- (2009). EVALUATION OF THE ROUTINE MEDICAL INTERVIEW TO IDENTIFY HEPATITIS C PATIENTS DEVELOPING MAJOR DEPRESSION DURING PEGINTERFERON ALFA-2A PLUS RIBAVIRIN TREATMENT USING THE MAJOR DEPRESSION INVENTORY. Journal of Hepatology. S154-S154.
- (2008). Twelve weeks of treatment is insufficient for HCV genotype 2 and 3 infected patients with steatosis. Journal of Hepatology. S314-S315.
- (2008). Ribavirin concentration at week four is an independend predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (NORDynamic trial). Journal of Hepatology. S6-S7.
- (2007). Peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The nordynamic trial. Hepatology. 815A-816A.
- (2007). Comparison of peginterferon alpha-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The nordynamic trial. Journal of Hepatology. S229-S229.
Poster
- (2018). Schistosomiasis in Norwegian medical students .
Academic literature review
- (2010). Giardiasis - why do the symptoms sometimes never stop? Trends in Parasitology. 75-82.
More information in national current research information system (CRIStin)
Fields of competence